Hepatitis Monthly

Published by: Kowsar

Persistence of Anti-HBs Among Palestinian Medical Students After 18 - 22 Years of Vaccination: A Cross-Sectional Study

Kamal Dumaidi 1 , * and Amer Al-Jawabreh 1 , 2
Authors Information
1 Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Arab American University, Jenin, Palestine
2 Al-Quds Public Health Society, Jerusalem, Palestine
Article information
  • Hepatitis Monthly: November 01, 2015, 15 (11); e29325
  • Published Online: November 7, 2015
  • Article Type: Research Article
  • Received: May 13, 2015
  • Revised: August 15, 2015
  • Accepted: August 29, 2015
  • DOI: 10.5812/hepatmon.29325

To Cite: Dumaidi K, Al-Jawabreh A. Persistence of Anti-HBs Among Palestinian Medical Students After 18 - 22 Years of Vaccination: A Cross-Sectional Study, Hepat Mon. 2015 ;15(11):e29325. doi: 10.5812/hepatmon.29325.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Hepatitis B fact sheet. 2012;
  • 2. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008; 359(14): 1486-500[DOI][PubMed]
  • 3. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther. 2010; 15 Suppl 3: 25-33[DOI][PubMed]
  • 4. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997; 337(24): 1733-45[DOI][PubMed]
  • 5. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005; 366(9494): 1379-84[DOI][PubMed]
  • 6. Centers for Disease C. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982; 31(24): 317-22[PubMed]
  • 7. Expanded Programme on Immunization Global Advisory Group. 1992;
  • 8. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ. 1997; 314(7086): 1033-6[PubMed]
  • 9. Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection. 2010; 38(5): 395-400[DOI][PubMed]
  • 10. Poovorawan Y, Theamboonlers A, Hirsch P, Vimolket T, Sinlaparatsamee S, Chaiear K, et al. Persistence of antibodies to the surface antigen of the hepatitis B virus (anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand. Ann Trop Med Parasitol. 2000; 94(6): 615-21[PubMed]
  • 11. Duval B, Gilca V, Boulianne N, De Wals P, Masse R, Trudeau G, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J. 2005; 24(3): 213-8[PubMed]
  • 12. Kao JH, Chen DS. Hepatitis B vaccination: to boost or not to boost? Lancet. 2005; 366(9494): 1337-8[DOI][PubMed]
  • 13. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study. J Infect Dis. 1997; 175(3): 674-7[PubMed]
  • 14. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis. 2003; 187(1): 134-8[DOI][PubMed]
  • 15. Young BW, Lee SS, Lim WL, Yeoh EK. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat. 2003; 10(1): 23-30[PubMed]
  • 16. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000; 355(9203): 561-5[PubMed]
  • 17. Recommendations of the Immunisation Practices Advisory Committee: Recommendations for protection against viral hepatitis. MMWR Morbid Mortal Wkly Rep. 1985; 34: 329-35
  • 18. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed. 1997; 77(1)-51[PubMed]
  • 19. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine. 2000; 18 Suppl 1-2[PubMed]
  • 20. Palestinian Ministry of Health. Annual Health Report in Palestine-2005. . Palestinian Health Information Center (PHIC). 2006;
  • 21. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis. 1999; 179(2): 489-92[DOI][PubMed]
  • 22. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol. 2007; 79(11): 1650-4[DOI][PubMed]
  • 23. Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol. 2009; 50(4): 805-16[DOI][PubMed]
  • 24. World Health Organization. . Position paper, Hepatitis B. Wkly Epidemiol Rec. 2009; 84: 405-20
  • 25. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006; 78(2): 169-77[DOI][PubMed]
  • 26. Behre U, Bleckmann G, Crasta PD, Leyssen M, Messier M, Jacquet JM, et al. Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination. Hum Vaccin Immunother. 2012; 8(6): 813-8[DOI][PubMed]
  • 27. Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008; 57(5): 404-9[DOI][PubMed]
  • 28. Al Ghamdi SS, Fallatah HI, Fetyani DM, Al-Mughales JA, Gelaidan AT. Long-term efficacy of the hepatitis B vaccine in a high-risk group. J Med Virol. 2013; 85(9): 1518-22[DOI][PubMed]
  • 29. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine. 2008; 26(51): 6587-91[DOI][PubMed]
  • 30. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2010; 28(3): 730-6[DOI][PubMed]
  • 31. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005; 142(5): 333-41[PubMed]
  • 32. Lu JJ, Cheng CC, Chou SM, Hor CB, Yang YC, Wang HL. Hepatitis B immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan. Vaccine. 2009; 27(47): 6613-8[DOI][PubMed]
  • 33. Norouzirad R, Shakurnia AH, Assarehzadegan MA, Serajian A, Khabazkhoob M. Serum levels of anti-hepatitis B surface antibody among vaccinated population aged 1 to 18 years in ahvaz city southwest of iran. Hepat Mon. 2014; 14(1)[DOI][PubMed]
  • 34. Su FH, Bai CH, Chu FY, Lin YS, Su CT, Yeh CC. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan. Vaccine. 2012; 30(27): 4034-9[DOI][PubMed]
  • 35. Annual Health Report- Palestine 2012 2013;
  • 36. Stein-Zamir C, Zentner G, Tallen-Gozani E, Grotto I. The Israel National Immunization Registry. Isr Med Assoc J. 2010; 12(5): 296-300[PubMed]
  • 37. Grosso G, Mistretta A, Marventano S, Ferranti R, Mauro L, Cunsolo R, et al. Long-term persistence of seroprotection by hepatitis B vaccination in healthcare workers of southern Italy. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 38. Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepat Mon. 2010; 10(1): 17-21[PubMed]
  • 39. Noubiap JJ, Nansseu JR, Kengne KK, Tchokfe Ndoula S, Agyingi LA. Occupational exposure to blood, hepatitis B vaccine knowledge and uptake among medical students in Cameroon. BMC Med Educ. 2013; 13: 148[DOI][PubMed]
  • 40. Ibrahim N, Idris A. Hepatitis B Awareness among Medical Students and Their Vaccination Status at Syrian Private University. Hepat Res Treat. 2014; 2014: 131920[DOI][PubMed]
  • 41. Pathoumthong K, Khampanisong P, Quet F, Latthaphasavang V, Souvong V, Buisson Y. Vaccination status, knowledge and awareness towards hepatitis B among students of health professions in Vientiane, Lao PDR. Vaccine. 2014; 32(39): 4993-9[DOI][PubMed]
  • 42. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States 2006;
  • 43. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments